Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 40,000 shares at $31.08 ($1.2M) on 2022-09-28, disclosed to the SEC on 2022-09-30.
Open-market sale of $1.2M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.74 | 15,577 | $479K | 38.8% |
| 2 | $30.74 | 15,577 | $479K | 38.8% |
| 3 | $31.08 | 4,423 | $137K | 11.2% |
| 4 | $31.08 | 4,423 | $137K | 11.2% |
| Total | $30.82 avg | 40,000 | $1.2M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |
| DNLI | SELL | 2022-07-27 | $712K | — | Filing → |